Acadia Q2 FY26 net income rises 18% to $32 million; net sales climb 16% to $308 million - ACAD News | Rallies
Acadia Q2 FY26 net income rises 18% to $32 million; net sales climb 16% to $308 million A ACAD • 2026-08-04 Quarterly results
ACADIA Pharmaceuticals posted Q2 GAAP total revenues of $308 million , up 16% year over year; net income rose to $32 million .
GAAP net sales climbed to $183 million for NUPLAZID , up 9% year over year; DAYBUE net sales rose to $125 million , up 30% .
R&D expense increased to $82 million ; SG&A expense climbed to $160 million .Cash, cash equivalents and investment securities totaled $956 million at June 30, 2026 .
Outlook and pipeline update
Raised full-year 2026 GAAP total revenue guidance to $1.24 billion-$1.3 billion ; cut R&D expense outlook to $355 million-$380 million .
Phase 2 remlifanserin topline results in Alzheimer's disease psychosis are expected in September to October 2026 ; the FDA granted Fast Track designation. •
2026-08-04
ACAD•
